Nobumasa Hino Selected Research

Mental Disorders (Mental Disorder)

1/2021

Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nobumasa Hino Research Topics

Disease

4	Inflammation (Inflammations) 01/2021 - 01/2018
2	Pathologic Neovascularization 01/2021 - 01/2020
1	Food Hypersensitivity (Food Allergy) 06/2023
1	Diarrhea 06/2023
1	Communicable Diseases (Infectious Diseases) 01/2023
1	Sepsis (Septicemia) 01/2023
1	Infections 01/2023
1	Mental Disorders (Mental Disorder) 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Neoplasms (Cancer) 01/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Cognitive Dysfunction 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Endotoxemia 01/2018
1	Hypersensitivity (Allergy) 07/2014
1	Asthma (Bronchial Asthma) 06/2012

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2020
1	Indicators and Reagents (Reagents)IBA 06/2023
1	PolyphenolsIBA 06/2023
1	theaflavinIBA 06/2023
1	AllergensIBA 06/2023
1	OvalbuminIBA 06/2023
1	TeaIBA 06/2023
1	CytokinesIBA 01/2023
1	KS-133IBA 01/2021
1	EndotoxinsIBA 01/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Type II Vasoactive Intestinal Peptide ReceptorsIBA 01/2021
1	Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP)IBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	LipopolysaccharidesIBA 01/2018
1	Deoxyribonucleases (DNase)FDA Link 07/2014
1	ChromatinIBA 07/2014
1	Interleukin-5 (Interleukin 5)IBA 06/2012

Therapy/Procedure

1	Immunotherapy 06/2023